Abstract
Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare intervention in this patient population, the use of adjunctive pharmacotherapeutic agents is often required. This article provides an overview of the first injectable treatment option, namely liraglutide, in the management of obesity, or of patients that are overweight in the presence of significant co-morbid conditions.
| Original language | English |
|---|---|
| Pages (from-to) | 38-40 |
| Number of pages | 3 |
| Journal | South African Family Practice |
| Volume | 58 |
| Issue number | 3 |
| Publication status | Published - 1 May 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- GLP-1
- Incretin
- Liraglutide
- Obesity
- Overweight
- Type 2 diabetes mellitus
- Weight-loss
Fingerprint
Dive into the research topics of 'Liraglutide for the treatment of obesity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver